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productsAbstract Two simple analytical techniques that manipulate the inherent spectroscopic properties
of the drug differently were developed for Clobetasol propionate (CP) determination in the presence
of its alkaline hydrolytic degradation products. The ﬁrst method depends on TLC-densitometric
determination of the UV–visualized bands after TLC separation of CP in the presence of its alkaline
degradation products in its bulk and pharmaceutical formulation. Separation was performed on
preactivated silica gel 60 F254 TLC plates using ethyl acetate:hexane:ammonia (5:5:0.2, by volume)
as a developing system followed by scanning at 240 nm. Linear correlation was obtained in the
range of 0.10–0.50 lg/band. The second method was ratio difference spectrophotometry. It was
applied by measuring the difference in peak amplitude of the ratio spectra at 243.40 and
256.40 nm. The selectivity of both methods was checked by analyzing laboratory prepared mixtures
containing different concentrations of CP and its alkaline degradation products. The methods were
validated in compliance with ICH guidelines. The methods determined CP in its bulk powder with
average percentage recoveries of 99.60%± 1.09 and 99.44%± 1.60 for densitometry and ratio dif-
ference, respectively. Both methods were successfully applied for quantiﬁcation of CP in its com-
mercial cream.
 2016 Publishing services provided by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Clobetasol propionate is a class 1 corticosteroid. It is a super-
potent synthetic di-halogenated analog of prednisolone.1–3 It is
1800 times more potent than hydrocortisone1 and is currently
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ket.2,4–8 Clobetasol propionate possesses potent anti-inﬂam-
matory,9,10 anti-pruritic and vaso-constrictive action.7 It is
used in the treatment of skin conditions such as severe psoria-
sis, seborrhoeic dermatitis, and extreme photodermatitis in
HIV/AIDS patients.11,12
Clobetasol propionate is 21-chloro-9a-ﬂuoro-11b, 17a-dihy
droxy-16b-methylpregna-1,4-diene-3,20-dione 17-propi-
onate,13–16 as shown in Fig. 1. Containing an ester linkage,
Clobetasol propionate is susceptible to hydrolysis to its corre-
sponding acid and alcohol.
Clobetasol propionate was analyzed using spectrophotom-
etry,17,18 HPTLC19–21 and HPLC.22–25 The Clobetasol propi-
onate degradation products were not identiﬁed in any of the
stability indicating studies that were conducted for CP deter-
mination according to our knowledge.
The International Conference on Harmonization (ICH)
Q1A (R2)26 guidelines entitled ‘‘stability testing of new drugs
substances and products” require the stress testing to be car-
ried out to elucidate the inherent stability characteristics of
the drug substance. A stability indicating method is a speciﬁc
method that quantiﬁes the standard drug alone and in the pres-
ence its degradation products. The information obtained from
the stability study may help to establish degradation patterns
during drug product development and the validation of analyt-
ical procedures.
The aim of this work was to identify the hydrolytic degra-
dation products of CP and to develop validated stability-
indicating methods for the determination of CP in the presence
of its degradation products to be used for quality control anal-
ysis of CP in bulk form and in its pharmaceutical formulation.
2. Experimental
2.1. Instruments
 Camag-Linomat 5 autosampler (Switzerland). Camag
microsyringe (100 lL). Camag TLC scanner 3 S/N 130319
with winCATS software, the following requirements are
taken into consideration:
– Slit dimensions: 5 mm  0.2 mm.
– Scanning speed: 20 mm/S.
– Spraying rate: 10 lL s1.
– Data resolution: 100 lm/step.
 Precoated TLC-plates, silica gel 60 F254 (20 cm  20 cm,
0.25 mm), E. Merck (Darmstadt-Germany). PH-meter,
Digital pH/MV/TEMP/ATC meter, Jenco Model-5005
(USA).Figure 1 Chemical structure of clobetasol 17-propionate
(C25H32ClFO5, MW= 467.0). A double beam UV–visible spectrophotometer (SHI-
MADZU, Japan), model UV-1800 PC with matched 1 cm
quartz cells, connected to an IBM-compatible PC and an
HP-600 inkjet printer. Bundled, UV-PC personal spec-
troscopy software version 2.43wasused toprocess the absorp-
tion and the derivative spectra. The spectral band width was
2 nm with wavelength-scanning speed of 2800 nm min1.
2.2. Materials and reagents
2.2.1. Pure standard
Clobetasol propionate, working standard, was kindly supplied
by GlaxoSmithKline Beecham, Cairo, Egypt. Its purity was
certiﬁed to be 100.00% according to a reported HPLC
method.24
Chlorocresol, working standard, was kindly supplied by,
GlaxoSmithKline Beecham Cairo, Egypt. Its purity was found
to be 100.00% according to its ofﬁcial USP method.14
2.2.2. Pharmaceutical formulation
Dermovate cream is a trade mark of GlaxoSmithKline group
companies, manufactured by SmithKline Beecham, Egypt.
Batch No. H101072, each 100 g cream was labeled to contain
0.05 g of CP.
2.2.3. Degraded sample
Degradation products were prepared under alkaline stress con-
dition by dissolving 100 mg of pure CP in the least amount of
methanol, reﬂuxing with 10 mL 0.1 N NaOH solution for 4 h
at temperature 100 C. The degradation process was followed
by TLC through the disappearance of the spot corresponding
to the drug and appearance of two new spots corresponding to
the formed degradation products using ethyl acetate:hexane:
ammonia (5:5:0.2, by volume) as a developing system. After
complete degradation, the solution was neutralized using
0.1 N HCl, evaporated nearly to dryness and the degradation
products were extracted with methanol 20 mL  4 times and
completed to 100 mL with methanol. Part of the mixed degra-
dation product solution was separated by preparative TLC
then scratched from the plate and extracted with methanol
to identify the degradation products.
2.2.4. Chemicals and reagents
All chemicals and reagents used throughout this work, were of
pure analytical grade.
Sodium hydroxide and hydrochloric acid, 0.1 N aqueous
solutions, hexane, ethyl acetate, and ammonia, 33% solution;
El-Nasr Pharmaceutical Chemicals Co., (Abu-Zabaal, Cairo,
Egypt). Methanol; spectroscopic grade; S.D. Fine-Chem Lim-
ited, (Mumbai, India). Methanol, HPLC-grade; E. Merck
(Darmstadt, Germany) and HPLC grade water.
2.3. Standard solutions
Stock standard solution of CP 0.1 mg mL1 in methanol for
both TLC-densitometric and spectrophotometric methods.
Stock standard solution of the alkaline degradation prod-
ucts derived from complete degradation of 100 mg CP to pre-
pare 0.1 mg mL1 standard solution of CP in methanol.
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methanol for ratio difference spectrophotometric method.
All stock standard solutions were freshly prepared on the
day of analysis and stored in refrigerator to be used within
24 h.
3. Procedures
3.1. Construction of calibration curve for TLC-densitometric
method
Aliquots equivalent to 0.10–0.50 mg from CP standard solu-
tion (0.1 mg mL1 in methanol) were transferred separately,
into a series of 10-mL measuring ﬂask and the volume was
completed with methanol. Ten micro liters of each solution
were applied in the form of bands on a TLC plate using a
Camag-Linomat IV applicator.
The bands were applied 14 mm apart from each other and
15 mm from the bottom edge of the plate with a length of
6 mm. Linear ascending development was performed in a chro-
matographic tank previously saturated with ethyl acetate:hex-
ane:ammonia (5:5:0.2, by volume) for 30 min at room
temperature. The developed plates were air-dried, then
scanned at 240 nm using deuterium lamp. A calibration curve
relating the optical density of each band to the corresponding
concentration of CP was constructed. The regression equation
was then computed for the studied drug and used for determi-
nation of samples containing unknown concentrations of CP.
3.2. Construction of calibration curve for ratio difference
spectrophotometric method
Aliquots of CP stock solution (0.1 mg mL1) equivalent to 25–
250 lg were accurately transferred into a series of 10-mL vol-
umetric ﬂasks then diluted to volume using methanol. The
absorption spectra of these solutions and the alkaline degrada-
tion products were divided by the absorption spectrum of
10 lg mL1 Chlorocresol (as a divisor) where the contribution
of the alkaline degradation products was removed. Calibration
graphs were constructed relating the difference in amplitude at
243.40 and 256.40 nm to the corresponding concentrations of
CP. The regression equation was then computed for the stud-
ied drug at the speciﬁed wavelengths and used for determina-
tion of samples containing unknown concentrations of CP.Figure 2 Suggested degradation products result from cleavage of e
alcohol and acid.3.3. Analysis of laboratory prepared mixtures containing
different ratios of Clobetasol propionate and its alkaline
degradation products using the suggested methods
Aliquots of intact drug and degradation products were mixed
to prepare different mixtures containing 10–50% (for TLC
method) and 2.5–30% of the degradation products (for ratio
difference method) then the procedures were completed as
mentioned under each method. The concentrations were calcu-
lated from the corresponding regression equations.
3.4. Assay of pharmaceutical formulations (Dermovate
cream)
Accurate weights of cream (0.60 g in 8 mL acetone for TLC
method and 0.20 g in 7 mL methanol for ratio difference
method) were melted in water bath at 60–70 C, then magnet-
ically stirred for 30 min, cooled in a refrigerator and ﬁltered.
The clear ﬁltrates were collected in separate 10 mL volumetric
ﬂasks. Appropriate volume of solvent (acetone for TLC
method and methanol for ratio difference method) was added
to prepare the ﬁnal concentration equivalent to 30 and
10 lg mL1 of CP for TLC and spectrophotometric determi-
nations, respectively.
4. Results and discussion
In pharmaceutical practice, quality means that the product to
be handled should be safe and effective. Stability studies
demonstrate that the necessary critical characteristics present
at the time of the release can be expected to be present when
the dosage form is administered. If safety and efﬁcacy values
decline, stability studies are the main judge that determines
when the product should be withdrawn from the market.
The ICH26 guidelines Q1A (R2) on ‘‘Stability Testing of
New Drug Substances” suggest that the testing of those fea-
tures which are susceptible to change during storage and are
likely to inﬂuence quality, safety and efﬁcacy must be done
by validated stability indicating methods. Forced degradation
was reported for CP, it was found that the drug degrades
under basic, oxidative, and light conditions.24 However the
degradation products have not been identiﬁed. The structural
characterization and synthesis of the degradation products
allow both to establish the degradation pathways and alsoster bond present in Clobetasol propionate to the corresponding
Figure 3 (a) IR spectrum of Clobetasol propionate. (b) IR spectrum of Clobetasol propionate alkaline degradation products.
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uct. Hence, in the present work the chemical degradation path-
way of CP was established and selective, precise and accurate
stability-indicating methods for the determination of CP in the
presence of its degradation products was also developed.
However, a recently published HPTLC method19 studied
the stability behavior of CP under different stress conditions.
But that method didn’t suggest the degradation pathway and
it didn’t isolate or identify the separated degradation products
under the studied conditions. Also the described methods in
this study have many advantages over that HPTLC method
as working in a wider range for CP determination, which indi-cates the high sensitivity of the methods. The reported method
also used more prolonged conditions, which results in dra-
matic degradation of the drug that does not occur in reality.
In this work, stress testing was carried out on CP using
alkaline hydrolysis; it was subjected to 0.1 N NaOH for 4 h
at 100 C. The degradation process under the previously men-
tioned conditions was followed up using TLC and the com-
pound was found to be liable to degradation under these
conditions giving two degradation products, as shown in
Fig. 2. The First degradation product was suggested to be Clo-
betasol, which is one of the CP impurities stated in BP (impu-
rity G),13 which will affect the topical: systemic potency ratio
Figure 4 1H NMR spectrum of Clobetasol propionate.
Figure 5 1H NMR spectrum of the ﬁrst Clobetasol propionate degradation product suggested to be Clobetasol, using methanol as
solvent.
Figure 6 1H NMR spectrum of the second Clobetasol propionate degradation product suggested to be Propionic acid, using methanol
as a solvent.
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local glucocorticoid activity and minimize CP systemic effects,
the corticosteroid skeleton was modiﬁed by esteriﬁcation at C-17 and produces an analog that is rapidly inactivated after its
systemic absorption.27 So, it is essential to develop analytical
procedure which will serve as a reliable, accurate and sensitive
Figure 7 (3D) Densitogram of Clobetasol propionate (Rf = 0.63) in the concentration range (0.10–0.50 lg/band), at 240 nm using ethyl
acetate:hexane:ammonia (5:5:0.2, by volume) as a developing system.
Figure 8 TLC chromatogram of Clobetasol propionate (0.45 lg/band, Rf = 0.63) and its alkaline degradation products (Deg. 1 & 2)
(0.50 lg/band, Rf = 0.30 & 0.56).
Table 1 Parameters of system suitability of the developed TLC-densitometric method for the determination of Clobetasol propionate
in the presence of its degradation products.
Parameters Degradation product
(1)
Degradation product
(2)
Clobetasol
propionate
Reference value29
Resolution (Rs) 7.20 1.73 >1
Separation factor
(a)
2.95 1.34 >1
Tailing factor (T) 1.00 1.00 1.00 =1 for typical symmetric peak
Capacity factor
(K΄)
2.33 0.79 0.59 The higher the capacity factor, the longer the
retention factor
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Development and validation of stability 171stability indicating method for the determination of CP in the
presence of its hydrolytic degradation products. The second
degradation product was suggested to be propionic acid.
These claims were conﬁrmed when the degradation prod-
ucts were identiﬁed using IR and 1H NMR spectrometry.
The IR spectrum of CP (Fig. 3a) shows a band corresponding
to the ester carbonyl group stretching at 1735 cm1 which dis-
appeared in the IR spectrum of degradation products
(Fig. 3b). The absence of this characteristic band is an evidence
of the cleavage of the ester bond.
The degradation products were identiﬁed separately by 1H
NMR spectrometry using methanol as a solvent. By compar-200.00 250.00 30
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Figure 9 Zero order spectra of 10 lg mL1 of Clobetasol propionate
using methanol as a blank.
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Figure 10 Ratio spectra of 10 lg mL1 of Clobetasol propionate (—
using the spectrum of 10 lg mL1 Chlorocresol in methanol as a divising the NMR spectrum of both CP (Fig. 4) and Clobetasol
(Fig. 5), it shows similar signals at both NMR spectra except
the signals at 2.29 and 1.14 ppm corresponding to aliphatic
protons in CH2 and CH3, respectively. The disappearance of
these signals is an evidence of the cleavage of the ester bond
and removal of CH3–CH2–CO part, which indicates the com-
plete degradation of CP and formation of the Clobetasol.
Fig. 6 represents the NMR spectrum of propionic acid; it
shows signals corresponding to the aliphatic protons in CH3
and CH2 at 1.79 and 2.06 ppm, respectively, besides the corre-
sponding signal to the carboxylic OH at 13.1 ppm.0.00 350.00 400.00
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Table 2 Determination of Clobetasol propionate in laboratory prepared mixtures by the proposed methods.
Degradation
products %
TLC-densitometric method Degradation
products %
Ratio diﬀerence method
Concentration (lg/band) Recovery % of
Clobetasol
propionate
Concentration (lg mL1) Recovery % of
Clobetasol
propionate
Degradation
products
Clobetasol
propionate
Degradation
products
Clobetasol
propionate
10 0.05 0.45 101.33 2.5 0.25 9.75 97.23
20 0.10 0.40 100.00 10 1.00 9.00 99.56
30 0.15 0.35 100.57 20 2.00 8.00 99.00
40 0.20 0.30 99.33 30 3.00 7.00 99.71
50 0.25 0.25 100.00
Mean ± SD 100.25%± 0.75 98.88%± 1.14
Table 3 Determination of Clobetasol propionate in Dermo-
vate cream by the proposed methods and application of
standard addition technique.
Pharmaceutical formulation TLC-
densitometric
method
Ratio
diﬀerence
method
Dermovate cream
0.05 g CP/100 g cream
Batch No. 101072
Found
%a
98.38 ± 2.15 101.30 ± 1.84
Recovery of standard added % a 100.89 ± 1.92 98.40 ± 1.65
a Average of three determinations.
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TLC-densitometry is an important technique in the ﬁeld of
separation and analysis of closely related compounds. This
method offers good results regarding accuracy, precision and
system suitability through scanning the chromatogram at the
maximum peak of CP (kmax 240 nm). Also, it allows quantiﬁ-
cation of a wide concentration range of CP. Good separation
was obtained using ethyl acetate:hexane:ammonia (5:5:0.2, by
volume) as a developing system as shown by the difference in
the retention factor (Rf) values of CP and its hydrolytic degra-
dation products (1 & 2) were Rf = 0.63, 0.30 and 0.56, respec-
tively, Fig. 7.
The suitable developing system for CP was found to be
ethyl acetate:hexane.20 To optimize the chromatographic
method different ratios were tried for separation e.g. (8:2, v/
v), (7:3, v/v) and (6:4, v/v), where complete separation of CP
and its degradation products were achieved using the ratio
(1:1, v/v). Different scanning wavelengths were tried, where
240 nm offers the best result regarding sensitivity, peak sym-
metry and sharpness, Fig. 8. The optimum band width chosen
was 6 mm and the inter-space between bands was 14 mm. Dif-
ferent slit dimensions were tried, where 5 mm  0.2 mm
proved to be the slit dimension of choice which provides the
highest sensitivity.
System suitability parameters including resolution (Rs),
peak symmetry, capacity factor (K0) and selectivity factor (a)
were calculated. The resolution was always above 1.5, the
selectivity more than one and an accepted value for symmetry
factor was obtained, Table 1. The linearity of CP was checked
at the selected wavelength 240 nm in the concentration range
of 0.1–0.5 lg/band. Calibration curve was constructed by plot-
ting the integrated peak areas versus the concentrations of CP
and the regression equation was calculated and found to be:
P ¼ 6521:80 Cþ 273:60 r ¼ 0:9992
where P is the integrated area under the peak for CP, C is the
concentration of CP in lg/band and r is the correlation
coefﬁcient.
4.2. Spectrophotometric methods
Direct spectrophotometry failed to determine CP in the pres-
ence of its alkaline degradation products, due to severe over-
lapping of their spectra Fig. 9. When ﬁrst derivative ratio
method (1DD) was applied as a stability indicating methodusing the degradation products as a divisor, it succeeded to
determine CP in the presence of its alkaline degradation prod-
ucts only in the bulk pure powder of CP. Accurate and valid
results were obtained, but upon applying the 1DD method
on the CP pharmaceutical formulation different results were
obtained rather than expected. By more investigations, it was
found that the presence of Chlorocresol as a preservative inter-
feres with the method. Many trails were applied to the 1DD
method in order to determine CP in the presence of both its
alkaline degradation products and its preservative Chlorocre-
sol, but all trails failed due to severe overlapping of their spec-
tra Fig. 9. This problem was solved by applying an alternative
spectrophotometric method which is a ratio difference spec-
trophotometric method.28
4.2.1. Ratio difference spectrophotometric method
Ratio difference method was developed for simultaneous
determination of CP in the presence of both its alkaline degra-
dation products and Chlorocresol (preservative) in CP bulk
powder and pharmaceutical formulation.
The utility of Ratio difference data processing is to calcu-
late the unknown concentration of a component of interest
present in a mixture with an unwanted interfering component
by calculating the peak amplitude difference between two
wavelengths on the ratio spectra. This is directly proportional
to the concentration of the component of interest, independent
of the interfering components. The pre‐requisite for the ratio
difference method is the careful selection of the divisor concen-
tration and the two such wavelengths where the interfering
component shows same absorbance whereas the component
Table 4 Assay validation parameters of the proposed meth-
ods for the determination of Clobetasol propionate.
Parameters TLC-densitometric
method
Ratio diﬀerence
method
Linearity
Slope 6521.8 0.04
Intercept 273.6 0.05
Correlation
coeﬃcient (r)
0.9992 0.9996
Accuracy (mean
± SD)
99.60 ± 1.09 99.44 ± 1.60
Precision (% RSD)
Repeatability* ±1.65 ±1.15
Intermediate
precision**
±0.89 ±1.11
Speciﬁcity and
selectivity
100.67 ± 1.09 98.88 ± 1.14
Range 0.10–0.50 lg/band 2.50–
25.00 lg mL1
Robustness*** 98.59 ± 1.43 –
LOD**** 0.01 lg/band 0.58 lg mL1
LOQ**** 0.04 lg/band 1.77 lg mL1
* The intraday (n= 9), average of three different concentrations
repeated three times within the day.
** The interday (n= 9), average of three concentrations repeated
three times in three successive days.
*** Robustness was determined by changing the developing system
to ethyl acetate:hexane (27:23, v/v).
**** Limit of detection and quantitation are determined via calcu-
lations, LOD= (SD of the response/slope)  3.3; LOQ= (SD of
the response/slope)  10.
Table 5 Statistical comparison of the results obtained by the
proposed methods and the reported HPLC method for the
determination of Clobetasol propionate in pure powder form.
TLC-
densitometric
method
Ratio diﬀerence
method
Reported
method 24*
Mean 99.6 99.44 99.54
SD 1.09 1.6 1.91
RSD% 1.09 1.61 1.92
n 9 9 9
Variance 1.19 2.56 3.65
F-value
p= 0.05
3.07 (3.44) 1.43 (3.44) –
Student’s
t-test
0.08 (2.12) 0.12 (2.12) –
– The ﬁgures between parenthesis are the corresponding theoretical
values of t and F at p= 0.05.
* HPLC method24 using C18 column, methanol: water (68:32 v/v)
as mobile phase, UV detection at 239 nm and a ﬂow rate of
0.9 mL min1.
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concentration.28
The ratio difference method was found to be simple, accu-
rate, economic and rapid. The interference of Chlorocresol was
canceled by dividing both CP and degradation product spectra
by the chosen concentration of Chlorocresol. After testingseveral divisors of Chlorocresol absorption spectra, best results
were obtained using a spectrum of 10 lg mL1. Then two
wavelengths on CP and its degradation products ratio spectra
were carefully selected at which the peak amplitude difference
of the degradation products is zero, as the peak amplitude is
the same for the degradation products at those two wave-
lengths. The difference in peak amplitude at 243.40 and
256.40 nm was selected for CP, where the difference is zero
for its degradation products, Fig. 10.
Linear relationship was obtained in the range of 2.5–
25 lg mL1 between the peak amplitude difference at 243.40
and 256.40 nm and the corresponding drug concentrations.
The regression equation was computed and found to be:
DP  A243:40256:40 nm ¼ 0:04 Cþ 0:05 r ¼ 0:9996
where DPA is the peak amplitude difference between 243.40
and 256.40 nm, C is the concentration of CP in lg mL1 and
r is the correlation coefﬁcient.
To assess the stability-indicating efﬁciency of the proposed
methods, the degradation products of CP and Chlorocresol
(preservative) were mixed with the intact drug in different
ratios and analyzed by the proposed methods. Table 2 illus-
trates good selectivity in the determination of CP in the pres-
ence of its alkaline degradation products by preparing
different mixtures containing 10–50% (for TLC method) and
2.5–30% of the degradation products (for the ratio difference
method).
The suggested methods were successfully applied for the
determination of CP in its pharmaceutical formulation, show-
ing good percentage recoveries. The validity of the suggested
methods was further assessed by applying the standard addi-
tion technique, Table 3. The suggested methods were validated
according to the ICH guidelines26 and the obtained results
were accurate, precise and more sensitive in comparison with
the other published work,19 Table 4. The results obtained by
the suggested methods were statistically compared to a
reported HPLC method24 and no signiﬁcant difference regard-
ing accuracy and precision was obtained, Table 5.
5. Conclusion
The present work was concerned with the determination of CP
in the presence of its alkaline degradation products where sim-
ple, sensitive and rapid methods were described for the deter-
mination of CP in its pure form and pharmaceutical
formulation according to the results obtained. The methods
were validated according to ICH guidelines.
The presented TLC-densitometric method could provide
highly selective quantitative stability indicating method for
the analysis of CP in the presence of its alkaline degradation
products. Different spectrophotometric methods were applied
for the determination of CP including 1DD method. Many
trails were applied to the 1DD method in order to determine
CP in the presence of both its alkaline degradation products
and its preservative Chlorocresol, but all trails failed due to
severe overlapping of their spectra. Alternative ratio difference
spectrophotometric method was developed. The proposed
ratio difference method showed accurate and precise results
and also provided the advantage of simultaneous determina-
tion of CP in the presence of both its alkaline degradation
products and Chlorocresol as a preservative. Both TLC-
174 Y.F. Bassuoni et al.densitometric and ratio difference methods have the advantage
of successfully determining CP in its available dosage form.
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